Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Democratic-led states defend a Biden rule for DACA immigrants' healthcare, US regulators propose reducing nicotine in ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ahead.